Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, GVS-111)

Noopept is a small synthetic compound that functions as a high-potency nootropic — the most-prescribed cognitive-enhancement medication in Russia and one of the better-studied compounds in the broader piracetam-derivative family.

Important framing: Noopept is technically peptide-adjacent rather than a true peptide. The molecule (N-phenylacetyl-L-prolylglycine ethyl ester) is a small dipeptide ester — a proline-glycine dipeptide core with attached groups that create a peptide-mimetic small molecule. It is covered on this site because the research-peptide and nootropic communities consistently classify it with peptide cognitive enhancers (Selank, Semax, Cerebrolysin, Cortexin, Dihexa). The peptide-community classification is functional (where the discussion happens) rather than chemical.

The principal active metabolite is cycloprolylglycine (CPG), which is itself an endogenous neuropeptide present in the human brain. This metabolic pathway is part of why Noopept's effects are often described as smoother and more "natural-feeling" than stimulant-class cognitive enhancers.

Noopept was developed in the 1990s by the Tatyana Gudasheva group at the Russian Academy of Medical Sciences as a piracetam derivative engineered for substantially higher potency and improved blood-brain barrier penetration. The original piracetam (developed by UCB in Belgium in the 1960s) established the racetam class as cognitive-modulating compounds; subsequent derivatives (aniracetam, oxiracetam, pramiracetam, phenylpiracetam, Noopept) progressively refined the pharmacology.

Noopept's structural innovation: appending an N-phenylacetyl group and modifying the molecular structure to create what is functionally a peptide-mimetic with a dipeptide-like core (proline-glycine) embedded in a small-molecule framework. This produces both improved CNS penetration and substantially higher receptor-binding affinity at the relevant targets.

The compound has been the most-prescribed nootropic in Russia for the past several decades, with substantial clinical use in post-stroke recovery, mild cognitive impairment, traumatic brain injury rehabilitation, and chronic cerebrovascular insufficiency. Western pharmaceutical interest has been limited, in part because of the difficulty of translating Russian clinical evidence into FDA-relevant trial frameworks and in part because the cognitive-enhancement regulatory pathway is uncertain.

Noopept's mechanism is multifactorial and not fully characterized at the receptor level:

• NGF and BDNF upregulation — Russian preclinical work demonstrates increased nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) expression in neural tissue following Noopept exposure. Both factors support neuronal survival, synapse formation, and learning consolidation.
• Cycloprolylglycine (CPG) metabolite activity — The principal active metabolite is an endogenous neuropeptide with its own activity at CNS targets. CPG may be responsible for much of the sustained cognitive effects.
• Cholinergic modulation — Like other racetam derivatives, Noopept modulates acetylcholine signaling, contributing to memory and learning effects.
• Glutamatergic effects — AMPA and NMDA receptor modulation has been characterized; long-term potentiation effects in hippocampal slices support a glutamatergic mechanism.
• Anxiolytic effects — Independent of the cognitive effects, Noopept has anxiolytic properties in animal models and in human reports, distinguishing it from pure cognitive enhancers.
• Neuroprotection — Reduced oxidative stress, mitochondrial protection, and reduced apoptotic signaling in neural tissue under stress conditions.

The compound is unusual in the nootropic space for the breadth of its proposed mechanisms — and unusual in actually having multiple converging lines of evidence rather than mechanism speculation.

Noopept has rapid oral absorption and CNS penetration. Plasma half-life of the parent compound is 30-60 minutes, but the principal active metabolite — cycloprolylglycine (CPG) — has substantially longer activity and may account for much of the sustained cognitive effects. CPG is itself an endogenous neuropeptide present in human brain, which is part of why Noopept's effects are often described as more "natural-feeling" than the broader stimulant cognitive-enhancer category.

The peer-reviewed literature on Noopept is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Russian clinical use: typically 10-30 mg per day in divided doses (commonly 10 mg twice or three times daily). Russian prescription tablets are typically 10 mg. Treatment courses are typically 6-8 weeks with cycling rather than indefinite continuous use, reflecting the documented tolerance development and the standard practice in racetam-class cognitive enhancers.

Research-peptide and nootropic community use follows similar dosing patterns. Sublingual administration is sometimes used for the powder form, leveraging the rapid absorption profile. Stacking with choline sources (alpha-GPC, citicoline) is common in nootropic community protocols, paralleling the standard practice for the broader racetam family.

Noopept is not FDA-approved and is not legally available by US prescription. It is sold internationally as a research chemical or supplement depending on jurisdiction; the regulatory landscape is complex and varies by state and country.

Noopept is one of the better-evidenced cognitive enhancers outside the FDA-approved space — the most-prescribed nootropic in Russia with substantial clinical evidence in cognitive impairment populations and a coherent multi-mechanism story involving NGF/BDNF upregulation, glutamatergic modulation, anxiolytic effects, and neuroprotection. The piracetam-derivative engineering produced substantially higher potency and CNS penetration than the original racetam compounds, and the cycloprolylglycine metabolite contributes endogenous-neuropeptide activity that explains the relatively smooth subjective profile.

For users in the cognitive-enhancement and nootropic space, Noopept sits in the "well-characterized small-molecule with peptide-adjacent classification, substantial Russian clinical evidence, thinner Western RCT validation, defensible safety profile at standard doses" category. It pairs naturally with the other cognitive peptides on the site — Selank (anxiolytic), Semax (cognitive enhancement and attention), Cerebrolysin (neuroprotection and recovery), Cortexin (cognitive recovery), Dihexa (the more aggressive BDNF-class candidate) — see the Semax + Selank Cognitive Stack for an established nootropic combination framework that Noopept can complement.

For cognitive impairment populations (post-stroke recovery, mild cognitive impairment, TBI rehabilitation), Noopept has substantial clinical evidence supporting use under qualified-practitioner supervision in jurisdictions where it is appropriately accessible. For healthy-adult cognitive enhancement, the evidence is thinner but the safety profile is favorable; the appropriate framework is short-cycle exploratory use rather than chronic indefinite administration.